20 results
8-K
EX-99.1
NKTX
Nkarta Inc
25 Mar 24
Regulation FD Disclosure
6:05am
in NHL NKX019 engineering allows cytokine independence, for both persistence and response, further enabling disease-tailored LD NK cells with membrane
PRE 14A
pybfscfr srj2
14 Apr 23
Preliminary proxy
5:00pm
DEF 14A
fcy1ctc1x yv
22 Apr 21
Definitive proxy
12:35pm
10-K
9kcof0mxxumj2l5qdo8
25 Mar 21
Annual report
12:00am
8-K
EX-3.2
lu56feu8gmb9mn3s
14 Jul 20
Amendments to Articles of Incorporation or Bylaws
4:10pm
424B4
un1b2zj5mo2agwi9buz
10 Jul 20
Prospectus supplement with pricing info
9:35pm
S-1/A
ylgvb nthqnyb
2 Jul 20
IPO registration (amended)
5:17pm
S-1/A
EX-3.4
p1oae7 zdl
2 Jul 20
IPO registration (amended)
5:17pm
S-1
fh6yyoqr4lz23br1ai4
19 Jun 20
IPO registration
3:24pm
DRS/A
g7qdu8eb48u7j
19 May 20
Draft registration statement (amended)
12:00am
DRS/A
yit5bc
20 Apr 20
Draft registration statement (amended)
12:00am
DRS
e9bxv686aw0b0kuty 6w
28 Feb 20
Draft registration statement
12:00am
- Prev
- 1
- Next